Ryan Martin, MD
Pulmonary Disease · Lincoln, NENPI 1790981082
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $514,095 of the $600,260 with a category attached, or 85.6%. AstraZeneca accounts for 91.1% of it on its own, with 38 other manufacturers making up the rest. 2025 is the largest year on record at $201,196, more than ten times the $4,355 reported in 2019. Among pulmonary disease clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 742 payments — averaging $808.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$547K
- Sanofi$27K
- Intuitive Surgical$19K
- GSK$4K
- Veran Medical Technologies, Inc.$798
- Jazz Pharmaceuticals Inc.$282
- plus $2K from 33 others
What the payments were for
- Consulting fees$10,9432%
- Speaking & faculty fees$514,09586%
- Travel & lodging$44,3717%
- Food & beverage$15,7353%
- Education$15,1163%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 503 | $546,892 |
| Sanofi | 33 | $27,222 |
| Intuitive Surgical | 35 | $18,730 |
| GSK | 49 | $4,447 |
| Veran Medical Technologies, Inc. | 6 | $798 |
| Jazz Pharmaceuticals Inc. | 17 | $282 |
| Grifols USA, LLC | 12 | $266 |
| Sunovion Pharmaceuticals Inc. | 14 | $246 |
| Amgen | 9 | $156 |
| Regeneron Healthcare Solutions, Inc. | 7 | $107 |
| Harmony Biosciences LLC | 5 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $92 |
| Inspire Medical Systems, Inc. | 1 | $87 |
| Boehringer Ingelheim | 6 | $86 |
| United Therapeutics Corporation | 4 | $68 |
| Verona Pharma, Inc. | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 3 | $52 |
| Insmed, Inc. | 3 | $49 |
| Resmed Corp | 1 | $48 |
| Boston Scientific | 3 | $43 |
| Pulmonx Corporation | 1 | $40 |
| Tactile Systems Technology Inc | 1 | $35 |
| Astellas Pharma US Inc | 2 | $34 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $29 |
| Merck | 2 | $29 |
| Philips North America LLC | 2 | $27 |
| Novartis | 2 | $27 |
| Baxter Healthcare | 1 | $26 |
| Electromed, Inc. | 3 | $24 |
| Circassia Inc. | 2 | $24 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Liquidia Technologies, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| AbbVie | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Ambu Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$314,728
- AIRSUPRA$180,138
- FASENRA$38,496
- DUPIXENT$31,143
- Da Vinci Surgical System$14,964
- NUCALA$4,020
- ION$3,000
- BREZTRI AEROSPHERE$1,400
- SYMBICORT$1,300
- Spin$712
- BEVESPI AEROSPHERE$650
- DALIRESP$650
- TAGRISSO$146
How this compares
$600,260 in reported general payments places this provider in the 95th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 291 | $238,612 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 283 | $198,092 |
| Breo ElliptaFluticasone/Vilanterol | 153 | $63,084 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 92 | $56,258 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 68 | $46,524 |
| Spiriva RespimatTiotropium Bromide | 40 | $27,984 |
| SymbicortBudesonide/Formoterol Fumarate | 66 | $19,694 |
| Spiriva HandihalerTiotropium Bromide | 20 | $10,884 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $8,708 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $7,275 |
| Roflumilast | 95 | $6,959 |
| Ventolin HfaAlbuterol Sulfate | 77 | $6,634 |
| BreynaBudesonide/Formoterol Fumarate | 30 | $5,589 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 186 | $5,110 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 43 | $4,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $4,447 | $365,230554 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $546,892 | $220,696360 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $86 | $74,508108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Lincoln
- Douglas FiedlerLincoln$23K
- Kevin ReichmuthLincoln$22K
- Harvey HopkinsLincoln$18K
- William JohnsonLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jakeb RiggleLincoln$13K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
- Jeffrey JarrettLincoln$5K
- Sean BarryLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.